These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

405 related articles for article (PubMed ID: 33913406)

  • 21. Treatment for cramps in amyotrophic lateral sclerosis/motor neuron disease.
    Baldinger R; Katzberg HD; Weber M
    Cochrane Database Syst Rev; 2012 Apr; (4):CD004157. PubMed ID: 22513921
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Exploring Molecular Approaches in Amyotrophic Lateral Sclerosis: Drug Targets from Clinical and Pre-Clinical Findings.
    Alam M; Yadav RK; Minj E; Tiwari A; Mehan S
    Curr Mol Pharmacol; 2021; 14(3):263-280. PubMed ID: 32342825
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Drug therapy for pain in amyotrophic lateral sclerosis or motor neuron disease.
    Brettschneider J; Kurent J; Ludolph A; Mitchell JD
    Cochrane Database Syst Rev; 2008 Jul; (3):CD005226. PubMed ID: 18646122
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Mechanical ventilation for amyotrophic lateral sclerosis/motor neuron disease.
    Radunovic A; Annane D; Rafiq MK; Brassington R; Mustfa N
    Cochrane Database Syst Rev; 2017 Oct; 10(10):CD004427. PubMed ID: 28982219
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Creatine for amyotrophic lateral sclerosis/motor neuron disease.
    Pastula DM; Moore DH; Bedlack RS
    Cochrane Database Syst Rev; 2010 Jun; (6):CD005225. PubMed ID: 20556761
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Mechanical ventilation for amyotrophic lateral sclerosis/motor neuron disease.
    Radunovic A; Annane D; Rafiq MK; Mustfa N
    Cochrane Database Syst Rev; 2013 Mar; (3):CD004427. PubMed ID: 23543531
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Motor neuron dysfunction in a mouse model of ALS: gender-dependent effect of P2X7 antagonism.
    Cervetto C; Frattaroli D; Maura G; Marcoli M
    Toxicology; 2013 Sep; 311(1-2):69-77. PubMed ID: 23583883
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Treatment of fatigue in amyotrophic lateral sclerosis/motor neuron disease.
    Gibbons C; Pagnini F; Friede T; Young CA
    Cochrane Database Syst Rev; 2018 Jan; 1(1):CD011005. PubMed ID: 29293261
    [TBL] [Abstract][Full Text] [Related]  

  • 29. CSF glial markers correlate with survival in amyotrophic lateral sclerosis.
    Süssmuth SD; Sperfeld AD; Hinz A; Brettschneider J; Endruhn S; Ludolph AC; Tumani H
    Neurology; 2010 Mar; 74(12):982-7. PubMed ID: 20308682
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Amyotrophic Lateral Sclerosis and Other Motor Neuron Diseases.
    Quinn C; Elman L
    Continuum (Minneap Minn); 2020 Oct; 26(5):1323-1347. PubMed ID: 33003004
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Amino acids for amyotrophic lateral sclerosis / motor neuron disease.
    Parton M; Mitsumoto H; Leigh PN
    Cochrane Database Syst Rev; 2003; (4):CD003457. PubMed ID: 14583978
    [TBL] [Abstract][Full Text] [Related]  

  • 32. WITHDRAWN: Amino acids for amyotrophic lateral sclerosis / motor neuron disease.
    Parton M; Mitsumoto H; Leigh PN
    Cochrane Database Syst Rev; 2008 Apr; (2):CD003457. PubMed ID: 18425887
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Medical technology assessment. Electrodiagnosis in motor neuron diseases and amyotrophic lateral sclerosis.
    de Carvalho M; Johnsen B; Fuglsang-Frederiksen A
    Neurophysiol Clin; 2001 Oct; 31(5):341-8. PubMed ID: 11817274
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Amyotrophic lateral sclerosis or not: Keys for the diagnosis.
    Lenglet T; Camdessanché JP
    Rev Neurol (Paris); 2017 May; 173(5):280-287. PubMed ID: 28461025
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Spirituality and/or religious faith: A means for coping with the effects of amyotrophic lateral sclerosis/motor neuron disease?
    O'Brien MR; Clark D
    Palliat Support Care; 2015 Dec; 13(6):1603-14. PubMed ID: 25851240
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Clemastine Confers Neuroprotection and Induces an Anti-Inflammatory Phenotype in SOD1(G93A) Mouse Model of Amyotrophic Lateral Sclerosis.
    Apolloni S; Fabbrizio P; Parisi C; Amadio S; Volonté C
    Mol Neurobiol; 2016 Jan; 53(1):518-531. PubMed ID: 25482048
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Guidelines in motor neurone disease (MND)/amyotrophic lateral sclerosis (ALS) - from diagnosis to patient care.
    Mitchell JD
    J Neurol; 2000 Dec; 247 Suppl 6():VI/7-12. PubMed ID: 19714406
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Recent progress towards an effective treatment of amyotrophic lateral sclerosis using the SOD1 mouse model in a preclinical setting.
    Browne EC; Abbott BM
    Eur J Med Chem; 2016 Oct; 121():918-925. PubMed ID: 27012524
    [TBL] [Abstract][Full Text] [Related]  

  • 39. TDP-43 is consistently co-localized with ubiquitinated inclusions in sporadic and Guam amyotrophic lateral sclerosis but not in familial amyotrophic lateral sclerosis with and without SOD1 mutations.
    Maekawa S; Leigh PN; King A; Jones E; Steele JC; Bodi I; Shaw CE; Hortobagyi T; Al-Sarraj S
    Neuropathology; 2009 Dec; 29(6):672-83. PubMed ID: 19496940
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Pathological TDP-43 distinguishes sporadic amyotrophic lateral sclerosis from amyotrophic lateral sclerosis with SOD1 mutations.
    Mackenzie IR; Bigio EH; Ince PG; Geser F; Neumann M; Cairns NJ; Kwong LK; Forman MS; Ravits J; Stewart H; Eisen A; McClusky L; Kretzschmar HA; Monoranu CM; Highley JR; Kirby J; Siddique T; Shaw PJ; Lee VM; Trojanowski JQ
    Ann Neurol; 2007 May; 61(5):427-34. PubMed ID: 17469116
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 21.